|
1）Foster GD, Wyatt HR, Klein S, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003; 348: 2082-90
|
|
|
|
2）Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial. Annals Intern Med. 2004; 140: 778-86
|
|
|
|
|
|
3）Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: A meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166: 285-93
|
|
|
|
|
|
4）Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet: Dietary Intervention Randomized Controlled Trial（DIRECT）Group. N Engl J Med. 2008; 359: 229-41
|
|
|
|
|
|
5）Schwarzfuchs D, Golan R, Shai I. Four-year follow-up after two-year dietary interventions. N Engl J Med. 2012; 367: 1373-4
|
|
|
|
|
|
6）Santos FL, Esteves SS, da Costa Pereira A, et al. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev. 2012; 13: 1048-66
|
|
|
|
|
|
7）Noto H, Goto A, Noda M, et al. Low-carbohydrate diets and all-cause mortality: A systemic review and meta-analysis of observational studies. PLoS One. 2013; 8: e55030
|
|
|
|
|
|
8）Fung TT, van Dam RM, Hankinson SE, et al. Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies. Ann Intern Med. 2010; 153: 289-98
|
|
|
|
|
|
9）Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368: 1279-90
|
|
|
|
|
|
10）日本糖尿病学会．「日本人の糖尿病食事療法に関する日本糖尿病学会の提言」．糖尿病．2013; 56: 1
|
|
|
|
|
11）Mozaffarian D, Hao T, Eric B, et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011; 364: 2392-404
|
|
|
|
|
|
12）Lee I-min, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012; 380: 219–29
|
|
|
|
|
|
13）Wen CP, Wai JOM, Rsai MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet. 2011; 378: 1244–53
|
|
|
|
|
|
14）World Cancer Research Fund / American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR, 2007
|
|
|
|
|
|
15）Pham NM, Mizoue T, Tanaka K, et al. Physical activity and colorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2012; 42: 2-13
|
|
|
|
|
|
16）Head D, Bugg JM, Goate AM, et al. Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. Arch Neurol. 2012; 69(5): 636-43
|
|
|
|
|
|
17）Rejeski, WJ, IP EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012; 366: 1209-17
|
|
|
|
|
|
18）Sone H, Tanaka S, Iimuro S, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010; 53: 419-28
|
|
|
|
|
|
19）Sone H, Tanaka S, Tanaka S, et al. Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS). Diabetologia. 2013; 56: 1021-30
|
|
|
|
|
|
20）Dolgin E. A history of drugs on the weight list. Nat Med. 2012; 18: 843
|
|
|
|
|
|
21）Carter R, Mouralidarane A, Ray S, et al. Recent advancements in drug treatment of obesity. Clin Med. 2012; 12: 456-60
|
|
|
|
|
|
22）Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363: 245-56
|
|
|
|
|
|
23）Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011; 96: 3067-77
|
|
|
|
|
|
24）OʼNeil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012; 20: 1426-36
|
|
|
|
|
|
25）Ryan DH, Bray GA. Pharmacologic treatment options for obesity: what is old is new again. Curr Hypertens Rep. 2013; 15: 182-9
|
|
|
|
|
|
26）Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012; 20: 330-42
|
|
|
|
|
|
27）Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377: 1341-52
|
|
|
|
|
|
28）Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012; 95: 297-308
|
|
|
|
|
|
29）Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010; 18: 108-15
|
|
|
|
|
|
30）Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013; 23: 427-36
|
|
|
|
|
|
31）Sjöström L, Narbro K, Sjöström D, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 357: 741-52
|
|
|
|
|
|
32）Vetter ML, et al. Narrative review: Effects of bariatric surgery on Type 2 diabetes mellitus. Ann Intern Med. 2009; 150: 94-103
|
|
|
|
|
|
33）Dixon JB, OʼBrien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes, a randomized controlled trial. JAMA. 2008; 299: 316-23
|
|
|
|
|
|
34）Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012; 366: 1567-76
|
|
|
|
|
|
35） Mingrone G, Panunzi Sgaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012; 366: 1577-85
|
|
|
|
|
|
36）Sasaki A, Wakabayashi G, Yonei Y. Current status of bariatric surgery in Japan and effectiveness in obesity and diabetes. J Gastroenterol. 2013 Apr 18. [Epub ahead of print]
|
|
|
|
|